

Screening project in Switzerland with Zenicor-ECG

Stockholm, 20 September 2017

This October, a project screening for atrial fibrillation will commence at the University Hospital in Friborg (HFR Fribourg), Switzerland. The project is the first screening project using Zenicor ECG in Switzerland and the aim is to improve the care of hospitalised patients by diagnosing atrial fibrillation in a more time and cost-effective way than has previously been done.

Hospitalised patients provide a suitable group for atrial fibrillation case finding since they commonly have an increased risk of atrial fibrillation and stroke due to high age and illnesses. In addition, the cost effectiveness of carrying out the project can be expected to be good as the patients are already in contact with healthcare.

- We are most pleased to be able to conduct the first screening project for atrial fibrillation in Switzerland, and the first of its kind in a hospital environment. The choice fell on Zenicor ECG due to its strong scientific validation, in addition to the system offering a flexible solution that is well adapted to our needs, says Medical Dr. Marco Mancinetti at HFR Fribourg.

The project uses a novel investigation flow of Zenicor Medical Systems, which is optimised to support screening of hospitalised patients among other areas of use. The system is designed to save time and resources and to enable quick assessment of high patient volumes in a limited time interval.

- We continuously work with product development and optimisation of the Zenicor ECG for different patient flows and care settings. In this case we have developed the Zenicor ECG to support a care pathway which allows early diagnosis of risk patients in a hospital setting that may otherwise have been overlooked, says Zenicor's CEO Mats Palerius, continuing:

- The development of new care pathways opens new markets and segments for us and this project is a crucial step for our continuous international expansion, concludes Mats Palerius.

About atrial fibrillation and stroke

Atrial fibrillation is the most common heart rhythm disturbance encountered by doctors. The condition is by itself not life-threatening, but it can be troublesome and requires action as patients left untreated have a five-fold increased risk of stroke. Official figures suggest that 1,000 people in Europe suffers a stroke caused by atrial fibrillation every day.

The burden of atrial fibrillation related strokes is large due to a high degree of untreated atrial fibrillations. The reason behind that is simply that the condition is hard to detect, one third of atrial fibrillations are symptom free and the condition may also come and go.

The good news is that the with diagnosis and proper treatment the risk of stroke can be reduced by more than 70 per cent.

About Zenicor and the Zenicor ECG System

Zenicor Medical Systems AB is a leading medical technology company in arrhythmia investigations and stroke prevention. Zenicor's ECG System is optimised for cardiac arrhythmia diagnosis, including atrial fibrillation, in professional healthcare and our system is in use in over 350 clinics in ten countries all over Europe. The efficiency of the solution has been documented in several studies and articles published in internationally leading scientific journals. These studies have shown that Zenicor's ECG System has superior diagnostic ability combined with cost-effectiveness and ease of use compared to traditional methods.

For more information, please contact:

Mats Palerius, CEO, Zenicor Medical Systems AB,
Phone: +46 70 561 55 64
E-mail: mats@zenicor.se

Dr. med. Marco Mancinetti, Consultant, Department of internal medicine Kantonspital HFR Fribourgh
E-mail: marco.mancinetti@h-fr.ch

High resolution images of Zenicor ECG are available for download: <http://zenicor.se/pressmaterial>

This information is such information that Zenicor Medical Systems AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 20 september CET.